Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts
As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 6,253,467 | $12,632,003 | 0.02% | |
| 2. | Sio Capital Michael Castor | 2,164,181 | $4,371,646 | +5% | 0.69% |
| 3. | DAFNA Capital Management Nathan Fischel | 1,567,561 | $3,166,473 | 0.74% | |
| 4. | Kynam Capital Derrick Tang | 1,566,317 | $3,163,960 | -6% | 0.2% |
| 5. | Ikarian Capital Neil Shahrestani | 1,492,229 | $3,014,301 | +68% | 0.24% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 150,000 | $243,000 | 0.01% | |
| 2. | 25,000 | $40,500 | 0% | |
| 3. | 20,000 | $32,400 | 0% | |
| 4. | 19,000 | $30,780 | 0% | |
| 5. | 10,000 | $16,200 | 0% |